Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
13 p, 861.9 KB Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation : The phase III TOURMALINE-MM4 trial / Dimopoulos, M.A. (Hematology and Medical Oncology. Department of Clinical Therapeutics. National and Kapodistrian University of Athens. School of Medicine) ; Špička, I. (First Department of Medicine. Department of Hematology. First Faculty of Medicine. Charles University. General Hospital in Prague) ; Quach, H. (Department of Hematology. University of Melbourne. St Vincent's Hospital) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Hájek, R. (Department of Hemato-oncology. University Hospital Ostrava. University of Ostrava. Faculty of Medicine) ; Garg, M. (Hematology. Leicester Royal Infirmary. University Hospitals of Leicester NHS Trust) ; Beksac, M. (Department of Hematology. Ankara University) ; Bringhen, S. (Division of Hematology. University of Torino. Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino) ; Katodritou, E. (Department of Hematology. Theagenion Cancer Hospital) ; Chng, W.J. (Department of Hematology-Oncology. National University Cancer Institute. National University Health System. Yong Loo Lin School of Medicine. Cancer Science Institute of Singapore. National University of Singapore) ; Leleu, X. (Pôle Régional de Cancérologie. Department of Haematology. Centre Hospitalier Universitaire La Milétrie-Poitiers) ; Iida, S. (Department of Hematology and Oncology. Nagoya City University. Graduate School of Medical Sciences) ; Mateos, M.V. (Hematology. Hospital Universitario de Salamanca. University Hospital of Salamanca. Centro de Investigación del Cáncer. Instituto de Biología Molecular y Celular del Cáncer. Universitario de Salamanca Consejo Superior de Investigaciones Científicas) ; Morgan, G. (Perlmutter Cancer Center. NYU Langone Health) ; Vorog, A. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Labotka, R. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Wang, B. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Palumbo, A. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Lonial, S. (Department of Hematology and Medical Oncology. Winship Cancer Institute of Emory University) ; Universitat Autònoma de Barcelona
PURPOSE Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has generally been limited to immunomodulatory agents. [...]
2020 - 10.1200/JCO.20.02060
Journal of Clinical Oncology, Vol. 38 Núm. 34 (january 2020) , p. 4030-4041  
2.
15 p, 655.6 KB Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM) : Clinical and Population Pharmacokinetic Analyses / Xu, X.S. (Janssen Research & Development. LLC) ; Moreau, P. (University Hospital of Nantes) ; Usmani, S.Z. (Levine Cancer Institute/Atrium Health) ; Lonial, S. (Winship Cancer Institute. Emory University) ; Jakubowiak, A. (University of Chicago Medical Center) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Krishnan, A. (City of Hope) ; Bladé, J. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Luo, M. (Janssen Research & Development. LLC) ; Sun, Y.N. (Janssen Research & Development. LLC) ; Zhou, H. (Janssen Research & Development. LLC) ; Nnane, I. (Janssen Research & Development. LLC) ; Deraedt, W. (Janssen Research & Development) ; Qi, M. (Janssen Research & Development. LLC) ; Ukropec, J. (Janssen Scientific Affairs. LLC) ; Clemens, P.L. (Janssen Research & Development. LLC) ; Universitat Autònoma de Barcelona
Introduction: Daratumumab, a human immunoglobulin Gκ monoclonal antibody targeting CD38, is approved as monotherapy and in combination with standard-of-care regimens for multiple myeloma. In clinical studies, the median durations of the first, second, and subsequent intravenous infusions of daratumumab were 7. [...]
2020 - 10.1007/s12325-020-01247-8
Advances in Therapy, Vol. 37 Núm. 4 (january 2020) , p. 1464-1478  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.